Solvonis Therapeutics shares jumped 7% to 0.15p after the company cleared the first hurdle in a US government testing programme. The update is an early regulatory/clinical milestone, supporting upside optionality but not yet reflecting final efficacy or commercial results.
Solvonis Therapeutics shares jumped 7% to 0.15p after the company cleared the first hurdle in a US government testing programme. The update is an early regulatory/clinical milestone, supporting upside optionality but not yet reflecting final efficacy or commercial results.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.28
Ticker Sentiment
